[Form 4] Enpro Inc. Insider Trading Activity
Rhea-AI Filing Summary
Enpro Inc. (NPO) — Form 4 insider filing dated 06/18/2025
Director John Humphrey reported two derivative transactions covering phantom stock that is part of his deferred compensation. Dividend-equivalent rights credited 15.9961 and 15 phantom stock units, respectively, at a reference price of $185.86 per unit. The combined 30.9961 units are valued at roughly $5.8 thousand.
Following the credits, Humphrey now beneficially owns 17,769.7614 phantom stock units, held directly. These units are pay-on-retirement instruments that vest or settle on the earliest of death, disability, or vesting of the related underlying award. No open-market purchases or sales of Enpro common stock were made; the “A” transaction code signifies an automatic, non-discretionary accrual under company plans.
- Transaction type: dividend-equivalent phantom stock credit
- Ownership change: +0.17% of personal phantom stock balance; immaterial to Enpro’s float
- Governance note: Filing appears timely and complete, with attorney-in-fact signature on 06/20/2025
Because the activity is routine compensation rather than active buying, the filing carries minimal investment significance and does not alter the fundamental outlook for NPO.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine phantom-stock accrual; tiny dollar amount, neutral for NPO valuation.
The filing records automatic dividend-equivalent credits tied to the director’s deferred-comp plan. At ≈$5.8 k, the addition is negligible relative to Enpro’s market cap and trading volume. No cash was exchanged, and no common shares changed hands. Investors should view this as a housekeeping disclosure rather than a sentiment signal. Impact on share supply, EPS, or governance risk is effectively zero.
TL;DR: Filing confirms compliant deferred-comp accrual; governance and Section 16 reporting appear sound.
The Phantom Stock units are credited 1-for-1 under two long-standing director compensation programs. The explanatory notes clearly identify vesting triggers and cumulative balance, demonstrating transparent disclosure practices. Signature authorization via attorney-in-fact is standard. No red flags such as back-dating, preferential pricing, or late filing are evident. Accordingly, the event is procedurally correct and non-impactful for shareholders.